In This Article:
We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Vera Therapeutics, Inc. (NASDAQ:VERA) stands against other top-performing stocks on Monday.
Vera Therapeutics jumped by 67.49 percent on Monday to close at $31.74 apiece following the success of its pivotal ORIGIN Phase 3 trial for Atacicept—a novel therapy for Berger’s disease, also known as immunoglobulin A nephropathy (IgAN).
In a statement, Vera Therapeutics, Inc. (NASDAQ:VERA) said that it achieved its primary endpoint of reduction in proteinuria (UPCR) during the trial, having decreased by 46 percent from baseline and by 42 percent compared with placebo at week 36.
A team of scientists in lab coats discussing research near a microscope and petri dishes.
Other pre-specified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial
Additionally, Vera Therapeutics, Inc. (NASDAQ:VERA) reported a favorable safety profile for the treatment.
According to the company, it plans to meet with the Food and Drug Administration (FDA) to discuss the results and the regulatory pathway, and submit a Biologics License Application (BLA) in the fourth quarter of 2025.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.